Background:
Multiple sclerosis is an autoimmune chronic inflammatory disease of the central nervous system
that can lead to some serious disabilities. Despite using various immunomodulatory and anti-inflammatory drugs that have
therapeutic effects, they cannot reduce its progression completely, and have some unwanted side effects too.
The immunomodulatory and anti-inflammatory effects of the β-D-Mannuronic acid [M2000] have been proven in several
surveys, and the present research was designed to determine its toxicity and therapeutic effects in MS patients.
Methods:
This study was performed on 15 MS patients who took 25 mg/kg/day the oral form of the β-D-Mannuronic acid
for six months, and 15 healthy people as a control group. Serum levels of Urea, Creatinine, GGT, Vitamin D3, Uric acid,
and Anti-Phospholipids were compared to evaluate the therapeutic and possible toxic effects of this drug after this period.
Results:
Non- toxic effects through the study of Urea, Creatinine, GGT, and non-significant changes in Uric acid and AntiPhospholipids levels, besides a significant rise in Vitamin, D3 levels in the M2000 treated cases were found.
Conclusions:
Our results suggested that β-D-Mannuronic acid is a safe drug and has no toxicity when administered orally
and also has some therapeutic effects in MS patients.
Anti‐inflammatory effects of hypoxia‐preconditioned human periodontal ligament cell secretome in an experimental model of multiple sclerosis: a key role of IL‐37